KNSA (Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by KNSA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | — |
| 2026-09-03 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-09-03 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-09-03 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-09-03 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-09-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | — |
| 2026-08-21 | Barry D Quart | Director | G | — | — |
| 2026-08-04 | Richard S Levy | Director | M | — | — |
| 2026-07-31 | G Bradley Cole | Director | MIXED | — | — |
| 2026-07-06 | Dhiraj H Malkani | CHIEF STRATEGY OFFICER | A | — | — |
| 2026-06-02 | G Bradley Cole | Director | M | — | — |
| 2026-06-02 | Tracey L McCain | Director | M | — | — |
| 2026-06-02 | Barry D Quart | Director | M | — | — |
| 2026-06-02 | Kimberly J Popovits | Director | M | — | — |
| 2026-06-02 | Richard S Levy | Director | M | — | — |
| 2026-06-02 | Sanj K Patel | CHAIRMAN & CEO | C | — | — |
| 2026-06-02 | Thomas Malley | Director | M | — | — |
| 2026-06-02 | FELIX BAKER | Director | A | — | — |
| 2026-05-05 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-01 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | — |
| 2026-04-29 | Barry D Quart | Director | MIXED | — | — |
| 2026-04-13 | Ross Moat | CHIEF OPERATING OFFICER | Sell | — | — |
| 2026-04-13 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sell | — | — |
| 2026-04-08 | Eben Tessari | CHIEF STRATEGY OFFICER | MIXED | — | — |
| 2026-04-08 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-04-08 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-04-08 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | — |
| 2026-04-08 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-04-08 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-04-08 | Barry D Quart | Director | MIXED | — | — |
| 2026-04-03 | Michael R Megna | CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-04-03 | Eben Tessari | CHIEF STRATEGY OFFICER | MIXED | — | — |
| 2026-04-03 | Ross Moat | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2026-04-03 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-04-03 | Sanj K Patel | CHAIRMAN & CEO | MIXED | — | — |
| 2026-04-03 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-03-11 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-03-04 | John F. Paolini | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-02-12 | Barry D Quart | Director | MIXED | — | — |
| 2026-02-11 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-04 | Richard S Levy | Director | M | — | — |
| 2026-02-04 | Barry D Quart | Director | MIXED | — | — |
| 2026-01-09 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-12-17 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2025-12-17 | Barry D Quart | Director | MIXED | — | — |
| 2025-12-10 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-12-01 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2025-11-19 | Eben Tessari | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2025-11-14 | Mark Ragosa | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-11-14 | Sanj K Patel | CHAIRMAN & CEO | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,759,734 | — |
| — | Director | 2,753,656 | — |
| — | Director | 900,443 | — |
| — | 10%+ Owner | 843,352 | — |
| — | EVP & Chief Legal Officer | 300,000 | — |
| — | Director | 138,912 | — |
| — | Director | 132,566 | — |
| — | President & COO | 116,187 | — |
| — | CHAIRMAN & CEO | 92,348 | — |
| — | Director | 87,312 | — |
| — | EVP & CFO | 79,589 | — |
| — | 10%+ Owner | 79,589 | — |
| — | CHIEF MEDICAL OFFICER | 69,922 | — |
| — | CHIEF ACCOUNTING OFFICER | 33,662 | — |
| — | CHIEF STRATEGY OFFICER | 23,976 | — |
| — | Director | 22,359 | — |
| — | CHIEF FINANCIAL OFFICER | 22,189 | — |
| — | Director | 15,345 | — |
| — | Director | 15,345 | — |
| — | CHIEF OPERATING OFFICER | 14,506 | — |
| — | Director | 12,745 | — |
| — | Director | 11,672 | — |
| — | Chief Commercial Officer | 5,176 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KNSA quote page; the site-wide leaderboard is on the insider transactions hub.